Diagnostic Value of Plasma M2-Pyruvate Kinase in Egyptian Patients with Colorectal Cancer
Wahib, A., Seif El-Nasr, M., Ismail, M., Eltiby, D., Sayed, S., Soliman, M. (2018). Diagnostic Value of Plasma M2-Pyruvate Kinase in Egyptian Patients with Colorectal Cancer. EKB Journal Management System, 73(11), 7997-8006. doi: 10.21608/ejhm.2018.21719
Ali Ahmed Wahib; Mohamed Safwat Seif El-Nasr; Mahmoud Bastawy Ismail; Diaa Mohammad Eltiby; Sayed Abd-Elrehim Sayed; Moataz Yousry Soliman. "Diagnostic Value of Plasma M2-Pyruvate Kinase in Egyptian Patients with Colorectal Cancer". EKB Journal Management System, 73, 11, 2018, 7997-8006. doi: 10.21608/ejhm.2018.21719
Wahib, A., Seif El-Nasr, M., Ismail, M., Eltiby, D., Sayed, S., Soliman, M. (2018). 'Diagnostic Value of Plasma M2-Pyruvate Kinase in Egyptian Patients with Colorectal Cancer', EKB Journal Management System, 73(11), pp. 7997-8006. doi: 10.21608/ejhm.2018.21719
Wahib, A., Seif El-Nasr, M., Ismail, M., Eltiby, D., Sayed, S., Soliman, M. Diagnostic Value of Plasma M2-Pyruvate Kinase in Egyptian Patients with Colorectal Cancer. EKB Journal Management System, 2018; 73(11): 7997-8006. doi: 10.21608/ejhm.2018.21719

Diagnostic Value of Plasma M2-Pyruvate Kinase in Egyptian Patients with Colorectal Cancer

The Egyptian Journal of Hospital Medicine
Article 18, Volume 73, Issue 11, October 2018, Page 7997-8006  XML PDF (933.71 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2018.21719
View on SCiNiTO View on SCiNiTO
Authors
Ali Ahmed Wahib1; Mohamed Safwat Seif El-Nasr1; Mahmoud Bastawy Ismail2; Diaa Mohammad Eltiby email 1; Sayed Abd-Elrehim Sayed3; Moataz Yousry Soliman1
1Departments of Tropical Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2Departments of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
3Departments of Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Abstract
Background: M2-pyruvate kinase (M2-PK) is a tumor growth key regulator and plays a crucial role in tumor metabolism and can dynamically regulate aerobic glycolsis. Notwithstanding, the colonoscopy is the gold standard for early detection of colorectal cancer (CRC), the acceptance of this invasive technique is low. Aim of the work: to assess the diagnostic value of plasma M2-PK in Egyptian patients with CRC. Methods: we measured the plasma M2-PK using Enzyme-linked immunosorbent assay in CRC patients and comparing these levels with those obtained from patients with functional bowel disorders (FBD), inflammatory bowel disease (IBD),colorectal polyp and apparently healthy individuals and to detect its sensitivity and specificity. Results: the value of plasma M2-PK level was higher in CRC patients, 15.22 U/ml than other groups. Average plasma M2-PK was 6.78, 5.28, 2.25 and 2.1 U/ml among colorectal polyp, IBD, FBD patients and normal individuals respectively. The plasma M2-PK can be used in differentiating between CRC and normal individual with  83.33% sensitivity, 100% specificity at area under the curve (AUC) 0.949  with cut-off >6U/ml. Also, it can be used to discriminate between colorectal polyp and CRC patients at cut-off level of >10.6 U/mL with 75.5% sensitivity and 87.5% specificity and to differentiate between FBD and organic colonic lesions at cut-off level >3 U/ml with 81.94% sensitivity and 83.3% specificity. Conclusion: plasma M2-PK was considerably elevated in CRC patients and may be used as non-invasive biomarker for CRC. Recommendation: future researches including a large and long-term follow-up studies are recommended.
Keywords
colorectal cancer; M2-pyruvate kinase; Functional bowel disorders; IBD; colorectal polyp
Statistics
Article View: 303
PDF Download: 742